Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Active, not recruitingOBSERVATIONAL
Enrollment

720

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

July 31, 2025

Conditions
HIV-Associated Malignant NeoplasmHIV InfectionsCancerAIDS Related LymphomaAIDS-related Kaposi SarcomaAIDS-Related MalignancyAnal CancerHPV-Related Malignancy
Interventions
OTHER

Non-Interventional

Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.

OTHER

Non-Interventional Follow-up

Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.

Trial Locations (16)

10010

Weill Cornell Medicine - Cornell Clinical Trials Unit, New York

10029

Mount Sinai Hospital, New York

10467

Montefiore Medical Center, The Bronx

19106

Abramson Cancer Center at Pennsylvania Hospital, Philadelphia

20037

George Washington University Cancer Center, Washington D.C.

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33612

Moffitt Cancer Center, Tampa

43210

The Ohio State University, Columbus

60612

University of Illinois at Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute - University of Utah, Salt Lake City

92903

Moores UCSD Cancer Center, La Jolla

98101

Virginia Mason Medical Center, Seattle

00921

University of Puerto Rico, San Juan

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

AIDS Malignancy Consortium

NETWORK